News & Insights – Mitodicure

Latest news

December 27, 2024

Mitodicure’s Chief Scientific Officer provides accumulated evidence on muscle pathophysiology in ME/CFS

Review article in the prestigious Journal of Cachexia, Sarcopenia and Muscle with Prof. Carmen Scheibenbogen.

May 2, 2024

Mitodicure discloses its therapeutic concept and leaves stealth mode

The Cause of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Is an Acquired Disorder of the Mitochondria within the Skeletal Muscle.

February 22, 2023

Mitodicure covered in ‘Health Rising’

ME/CFS Muscle Study Results in Drug Company Startup (by Cort Johnson on 'Health Rising').

Select publications

Scheibenbogen, C. and Wirth, K. J., ‘Key Pathophysiological Role of Skeletal Muscle Disturbance in Post COVID and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): Accumulated Evidence’, J Cachexia Sarcopenia Muscle, 2025;16:e13669.

Wirth, K. J. and Löhn, M., ‘Microvascular capillary and precapillary cardiovascular disturbances strongly interact to severely affect tissue perfusion and mitochondrial function in ME/CFS evolving from the Post-COVID-19 Syndrome’, Medicina (Kaunas), 2024 Jan 23;60(2):194.

Petter, E. et al., ‘Muscle Sodium Content in Patients with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome’, J Transl Med, 2022 Dec 9;20(1):580.

Wirth, K. J. and Scheibenbogen, C., ‘Pathophysiology of skeletal muscle disturbances in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)’, J Transl Med, 2021 Apr 21;19(1):162.

Wirth, K. J. and Scheibenbogen, C., ‘A Unifying Hypothesis of the Pathophysiology of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): Recognitions from the finding of autoantibodies against β2-adrenergic receptors’, Autoimmun Rev, 2020 Jun;19(6):102527.